Compass Therapeutics Stock Investor Sentiment

CMPX Stock  USD 1.50  0.01  0.67%   
Slightly above 63% of all Compass Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Compass Therapeutics suggests that some traders are interested. Compass Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Compass Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Compass Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Compass Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Compass Therapeutics Inc. has risen 12.08 percent Wednesday In Premarket Trading - InvestorsObserver
Google News at Macroaxis
over six months ago at finance.yahoo.com         
With 52 percent ownership of the shares, Compass Therapeutics, Inc. is heavily dominated by institut...
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Boylan James P of 40000 shares of Compass Therapeutics at 1.96 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Compass Therapeutics, Inc. Shares Acquired by Connor Clark Lunn Investment Management Ltd. - Defense...
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Yahoo News
over six months ago at benzinga.com         
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispe...
benzinga news
over six months ago at www.macroaxis.com         
Compass Therapeutics exotic insider transaction detected
Macroaxis News
over six months ago at thelincolnianonline.com         
Compass Therapeutics, Inc. Shares Sold by Monashee Investment Management LLC
news
over six months ago at thelincolnianonline.com         
Acquisition by Lindahl Richard S of 40000 shares of Compass Therapeutics subject to Rule 16b-3
news
over six months ago at www.macroaxis.com         
Acquisition by Chiniara Ellen of 40000 shares of Compass Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Were Hopeful That Compass Therapeutics Will Use Its Cash Wisely - Simply Wall St
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Payment of 49198 shares by Biskerleib Vered of Compass Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at zacks.com         
Compass Therapeutics, Inc. Upgraded to Buy Heres What You Should Know
zacks News
over six months ago at news.google.com         
Were Not Very Worried About Compass Therapeutics Cash Burn Rate - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Short Interest in Compass Therapeutics, Inc. Grows By 8.1 percent - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Compass Therapeutics that are available to investors today. That information is available publicly through Compass media outlets and privately through word of mouth or via Compass internal channels. However, regardless of the origin, that massive amount of Compass data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Compass Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Compass Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Compass Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Compass Therapeutics alpha.

Compass Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of tradable shares by Gray Mary Ann of Compass Therapeutics subject to Rule 16b-3
09/05/2024
2
Acquisition by Ferneau Philip of 30000 shares of Compass Therapeutics at 2.4 subject to Rule 16b-3
09/09/2024
3
Compass Therapeutics, Inc. Short Interest Up 23.7 percent in September - MarketBeat
09/30/2024
4
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
11/12/2024
5
Janus Henderson Group PLCs Strategic Reduction in Compass Therapeutics Inc Holdings
11/14/2024
6
Acquisition by Gordon Carl L of 60000 shares of Compass Therapeutics at 3.93 subject to Rule 16b-3
11/22/2024

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.